Novel CD28 antagonist mPEG PV1-Fab' mitigates experimental autoimmune uveitis by suppressing CD4+ T lymphocyte activation and IFN-γ production.
Autoimmune Uveitis is an important chronic inflammatory disease and a leading cause of impaired vision and blindness. This ocular autoimmune disorder is mainly mediated by T CD4+ lymphocytes poising a TH1 phenotype. Costimulatory molecules are known to play an important role on T cell activation and...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2017-01-01
|
| Series: | PLoS ONE |
| Online Access: | http://europepmc.org/articles/PMC5331984?pdf=render |
| _version_ | 1818115561597435904 |
|---|---|
| author | Pedro Henrique Papotto Eliana Blini Marengo Luiz Roberto Sardinha Karina Inácio Carvalho Ana Eduarda Zulim de Carvalho Sheyla Castillo-Mendez Carina Calixto Jank Bernard Vanhove Anna Carla Goldberg Luiz Vicente Rizzo |
| author_facet | Pedro Henrique Papotto Eliana Blini Marengo Luiz Roberto Sardinha Karina Inácio Carvalho Ana Eduarda Zulim de Carvalho Sheyla Castillo-Mendez Carina Calixto Jank Bernard Vanhove Anna Carla Goldberg Luiz Vicente Rizzo |
| author_sort | Pedro Henrique Papotto |
| collection | DOAJ |
| description | Autoimmune Uveitis is an important chronic inflammatory disease and a leading cause of impaired vision and blindness. This ocular autoimmune disorder is mainly mediated by T CD4+ lymphocytes poising a TH1 phenotype. Costimulatory molecules are known to play an important role on T cell activation and therefore represent interesting therapeutical targets for autoimmune disorders. CD28 is the prototypical costimulatory molecule for T lymphocytes, and plays a crucial role in the initiation, and maintenance of immune responses. However, previous attempts to use this molecule in clinical practice achieved no success. Thus, we evaluated the efficacy of mPEG PV1-Fab' (PV1), a novel selective CD28 antagonist monovalent Fab fragment in the treatment of Experimental Autoimmune Uveitis (EAU). Here, we showed that PV1 treatment decreases both average disease score and incidence of EAU. A decrease in the activation profile of both T CD4+ and T CD8+ eye-infiltrating lymphocytes was evidenced. In the periphery, T CD4+ cells from PV1-treated mice also showed a decrease in their activation status, with reduced expression of CD69, CD25, and PD-1 molecules. This suppression was not dependent on Treg cells, as both their frequency and absolute number were lower in PV1-treated mice. In addition, frequency of CD4+IFN-γ+ T cells was significantly lower in PV1-treated group, but not of IL-17-producing T cells. Moreover, after specific restimulation, PV1 blockade selectively blocked IFN-γ production by CD4+ lymphocytes Taken together, our data suggest that mPEG PV1-Fab' acts mainly on IFN-γ-producing CD4+ T cells and emphasize that this specific CD28 blockade strategy is a potential specific and alternative tool for the treatment of autoimmune disorders in the eye. |
| first_indexed | 2024-12-11T04:08:35Z |
| format | Article |
| id | doaj.art-634d5d8eb6344b278a1db7c8c47e5bdd |
| institution | Directory Open Access Journal |
| issn | 1932-6203 |
| language | English |
| last_indexed | 2024-12-11T04:08:35Z |
| publishDate | 2017-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj.art-634d5d8eb6344b278a1db7c8c47e5bdd2022-12-22T01:21:28ZengPublic Library of Science (PLoS)PLoS ONE1932-62032017-01-01123e017182210.1371/journal.pone.0171822Novel CD28 antagonist mPEG PV1-Fab' mitigates experimental autoimmune uveitis by suppressing CD4+ T lymphocyte activation and IFN-γ production.Pedro Henrique PapottoEliana Blini MarengoLuiz Roberto SardinhaKarina Inácio CarvalhoAna Eduarda Zulim de CarvalhoSheyla Castillo-MendezCarina Calixto JankBernard VanhoveAnna Carla GoldbergLuiz Vicente RizzoAutoimmune Uveitis is an important chronic inflammatory disease and a leading cause of impaired vision and blindness. This ocular autoimmune disorder is mainly mediated by T CD4+ lymphocytes poising a TH1 phenotype. Costimulatory molecules are known to play an important role on T cell activation and therefore represent interesting therapeutical targets for autoimmune disorders. CD28 is the prototypical costimulatory molecule for T lymphocytes, and plays a crucial role in the initiation, and maintenance of immune responses. However, previous attempts to use this molecule in clinical practice achieved no success. Thus, we evaluated the efficacy of mPEG PV1-Fab' (PV1), a novel selective CD28 antagonist monovalent Fab fragment in the treatment of Experimental Autoimmune Uveitis (EAU). Here, we showed that PV1 treatment decreases both average disease score and incidence of EAU. A decrease in the activation profile of both T CD4+ and T CD8+ eye-infiltrating lymphocytes was evidenced. In the periphery, T CD4+ cells from PV1-treated mice also showed a decrease in their activation status, with reduced expression of CD69, CD25, and PD-1 molecules. This suppression was not dependent on Treg cells, as both their frequency and absolute number were lower in PV1-treated mice. In addition, frequency of CD4+IFN-γ+ T cells was significantly lower in PV1-treated group, but not of IL-17-producing T cells. Moreover, after specific restimulation, PV1 blockade selectively blocked IFN-γ production by CD4+ lymphocytes Taken together, our data suggest that mPEG PV1-Fab' acts mainly on IFN-γ-producing CD4+ T cells and emphasize that this specific CD28 blockade strategy is a potential specific and alternative tool for the treatment of autoimmune disorders in the eye.http://europepmc.org/articles/PMC5331984?pdf=render |
| spellingShingle | Pedro Henrique Papotto Eliana Blini Marengo Luiz Roberto Sardinha Karina Inácio Carvalho Ana Eduarda Zulim de Carvalho Sheyla Castillo-Mendez Carina Calixto Jank Bernard Vanhove Anna Carla Goldberg Luiz Vicente Rizzo Novel CD28 antagonist mPEG PV1-Fab' mitigates experimental autoimmune uveitis by suppressing CD4+ T lymphocyte activation and IFN-γ production. PLoS ONE |
| title | Novel CD28 antagonist mPEG PV1-Fab' mitigates experimental autoimmune uveitis by suppressing CD4+ T lymphocyte activation and IFN-γ production. |
| title_full | Novel CD28 antagonist mPEG PV1-Fab' mitigates experimental autoimmune uveitis by suppressing CD4+ T lymphocyte activation and IFN-γ production. |
| title_fullStr | Novel CD28 antagonist mPEG PV1-Fab' mitigates experimental autoimmune uveitis by suppressing CD4+ T lymphocyte activation and IFN-γ production. |
| title_full_unstemmed | Novel CD28 antagonist mPEG PV1-Fab' mitigates experimental autoimmune uveitis by suppressing CD4+ T lymphocyte activation and IFN-γ production. |
| title_short | Novel CD28 antagonist mPEG PV1-Fab' mitigates experimental autoimmune uveitis by suppressing CD4+ T lymphocyte activation and IFN-γ production. |
| title_sort | novel cd28 antagonist mpeg pv1 fab mitigates experimental autoimmune uveitis by suppressing cd4 t lymphocyte activation and ifn γ production |
| url | http://europepmc.org/articles/PMC5331984?pdf=render |
| work_keys_str_mv | AT pedrohenriquepapotto novelcd28antagonistmpegpv1fabmitigatesexperimentalautoimmuneuveitisbysuppressingcd4tlymphocyteactivationandifngproduction AT elianablinimarengo novelcd28antagonistmpegpv1fabmitigatesexperimentalautoimmuneuveitisbysuppressingcd4tlymphocyteactivationandifngproduction AT luizrobertosardinha novelcd28antagonistmpegpv1fabmitigatesexperimentalautoimmuneuveitisbysuppressingcd4tlymphocyteactivationandifngproduction AT karinainaciocarvalho novelcd28antagonistmpegpv1fabmitigatesexperimentalautoimmuneuveitisbysuppressingcd4tlymphocyteactivationandifngproduction AT anaeduardazulimdecarvalho novelcd28antagonistmpegpv1fabmitigatesexperimentalautoimmuneuveitisbysuppressingcd4tlymphocyteactivationandifngproduction AT sheylacastillomendez novelcd28antagonistmpegpv1fabmitigatesexperimentalautoimmuneuveitisbysuppressingcd4tlymphocyteactivationandifngproduction AT carinacalixtojank novelcd28antagonistmpegpv1fabmitigatesexperimentalautoimmuneuveitisbysuppressingcd4tlymphocyteactivationandifngproduction AT bernardvanhove novelcd28antagonistmpegpv1fabmitigatesexperimentalautoimmuneuveitisbysuppressingcd4tlymphocyteactivationandifngproduction AT annacarlagoldberg novelcd28antagonistmpegpv1fabmitigatesexperimentalautoimmuneuveitisbysuppressingcd4tlymphocyteactivationandifngproduction AT luizvicenterizzo novelcd28antagonistmpegpv1fabmitigatesexperimentalautoimmuneuveitisbysuppressingcd4tlymphocyteactivationandifngproduction |